217 related articles for article (PubMed ID: 23907312)
1. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
[TBL] [Abstract][Full Text] [Related]
2. Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Berk V; Deniz K; Bozkurt O; Ozaslan E; Karaca H; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(14):6149-54. PubMed ID: 26320510
[TBL] [Abstract][Full Text] [Related]
3. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer.
Chang JY; Kim JH; Kang J; Park Y; Park SJ; Cheon JH; Kim WH; Kim H; Park JJ; Kim TI
Yonsei Med J; 2020 Jul; 61(7):572-578. PubMed ID: 32608200
[TBL] [Abstract][Full Text] [Related]
4. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Liu YS; Hsu HC; Tseng KC; Chen HC; Chen SJ
Biomed Pharmacother; 2013 Oct; 67(8):791-9. PubMed ID: 24138824
[TBL] [Abstract][Full Text] [Related]
5. Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.
Melling N; Simon R; Izbicki JR; Terracciano LM; Bokemeyer C; Sauter G; Marx AH
Int J Clin Exp Pathol; 2015; 8(6):7009-15. PubMed ID: 26261591
[TBL] [Abstract][Full Text] [Related]
6. A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells.
D'Angelo L; Piazzi G; Pacilli A; Prossomariti A; Fazio C; Montanaro L; Graziani G; Fogliano V; Munarini A; Bianchi F; Belluzzi A; Bazzoli F; Ricciardiello L
Carcinogenesis; 2014 Oct; 35(10):2314-20. PubMed ID: 25123131
[TBL] [Abstract][Full Text] [Related]
7. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Atreya CE; Ducker GS; Feldman ME; Bergsland EK; Warren RS; Shokat KM
Invest New Drugs; 2012 Dec; 30(6):2219-25. PubMed ID: 22270257
[TBL] [Abstract][Full Text] [Related]
8. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
9. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
10. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
11. Sex determining region Y-box 2 inhibits the proliferation of colorectal adenocarcinoma cells through the mTOR signaling pathway.
Liu H; Du L; Wen Z; Yang Y; Li J; Dong Z; Zheng G; Wang L; Zhang X; Wang C
Int J Mol Med; 2013 Jul; 32(1):59-66. PubMed ID: 23599173
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.
Fukuchi M; Kuwabara K; Tsuji Y; Baba H; Ishibashi K; Chika N; Hatano S; Matsuzawa T; Kumamoto K; Kumagai Y; Mochiki E; Ishida H
Anticancer Res; 2013 Nov; 33(11):5051-5. PubMed ID: 24222149
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.
Iwaya T; Yokobori T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Sawada G; Takahashi Y; Ishibashi M; Wakabayashi G; Mori M; Mimori K
Carcinogenesis; 2012 Dec; 33(12):2391-7. PubMed ID: 22983984
[TBL] [Abstract][Full Text] [Related]
14. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.
Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF
Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
[TBL] [Abstract][Full Text] [Related]
17. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.
Alqurashi N; Gopalan V; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2089-96. PubMed ID: 23773481
[TBL] [Abstract][Full Text] [Related]
18. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
Chang TC; Yeh CT; Adebayo BO; Lin YC; Deng L; Rao YK; Huang CC; Lee WH; Wu AT; Hsiao M; Wu CH; Wang LS; Tzeng YM
Toxicol Appl Pharmacol; 2015 Oct; 288(2):258-68. PubMed ID: 26235807
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
20. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor.
Hugen N; Verhoeven RH; Lemmens VE; van Aart CJ; Elferink MA; Radema SA; Nagtegaal ID; de Wilt JH
Int J Cancer; 2015 Jan; 136(2):333-9. PubMed ID: 24841868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
